| scholarly article | Q13442814 |
| P2093 | author name string | Diana Röhrborn | |
| Juergen Eckel | |||
| Nina Wronkowitz | |||
| P2860 | cites work | Obesity, Metabolic Syndrome, and Cardiovascular Disease | Q22241664 |
| Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation | Q22254628 | ||
| One site mutation disrupts dimer formation in human DPP-IV proteins | Q24305361 | ||
| Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers | Q24319154 | ||
| The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices | Q24323082 | ||
| Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26 | Q24323818 | ||
| Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation | Q24561372 | ||
| The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism | Q27640960 | ||
| A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site | Q27684194 | ||
| Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes | Q27689597 | ||
| Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders | Q28116286 | ||
| Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family | Q28199376 | ||
| Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats | Q28286911 | ||
| Glucose regulation of dipeptidyl peptidase IV gene expression is mediated by hepatocyte nuclear factor-1alpha in epithelial intestinal cells | Q28289423 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats | Q28574165 | ||
| The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site | Q28578376 | ||
| Domain‐Specific N‐Glycosylation of the Membrane Glycoprotein Dipeptidylpeptidase IV (CD26) Influences its Subcellular Trafficking, Biological Stability, Enzyme Activity and Protein Folding | Q28582112 | ||
| Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity | Q28728101 | ||
| Liver fibrosis | Q29547449 | ||
| Mechanisms of hepatic fibrogenesis | Q29619336 | ||
| Adipose tissue as an endocrine organ | Q29620407 | ||
| Circulating CD26 is negatively associated with inflammation in human and experimental arthritis | Q31144845 | ||
| Physical exercise reduces the expression of RANTES and its CCR5 receptor in the adipose tissue of obese humans | Q33594449 | ||
| Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker | Q33678705 | ||
| Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides | Q33788748 | ||
| Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. | Q33845786 | ||
| CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. | Q33892260 | ||
| Pancreatic beta cells synthesize neuropeptide Y and can rapidly release peptide co-transmitters | Q33894840 | ||
| Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. | Q38401198 | ||
| Incretin-based therapies for obesity treatment | Q38527160 | ||
| DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation | Q38870486 | ||
| Substance P promotes diabetic corneal epithelial wound healing through molecular mechanisms mediated via the neurokinin-1 receptor | Q38976880 | ||
| Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice | Q39207307 | ||
| Quantification of intact and truncated stromal cell-derived factor-1α in circulation by immunoaffinity enrichment and tandem mass spectrometry | Q39255466 | ||
| Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression. | Q39310752 | ||
| Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway | Q39636280 | ||
| Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus | Q39694021 | ||
| Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. | Q39778606 | ||
| Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. | Q39990285 | ||
| Distribution of GLP-1 and PACAP receptors in human tissues | Q41130734 | ||
| Clinical audit of patients using DPP4 inhibitors in longstanding type 2 diabetes | Q41731913 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report | Q42322703 | ||
| The role of adenosine in insulin action coupling in rat adipocytes | Q42502703 | ||
| The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats | Q42533774 | ||
| Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. | Q42589786 | ||
| Human dipeptidyl peptidase IV gene promoter: tissue-specific regulation from a TATA-less GC-rich sequence characteristic of a housekeeping gene promoter | Q42822338 | ||
| Insulinotropin PACAP potentiates insulin action. Stimulation of glucose uptake in 3T3-LI adipocytes | Q42831876 | ||
| Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis | Q42987834 | ||
| The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. | Q43140566 | ||
| Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes | Q43194107 | ||
| The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization | Q43804777 | ||
| Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor | Q44079524 | ||
| Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans | Q44230026 | ||
| Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury | Q44369782 | ||
| Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes | Q44576271 | ||
| Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. | Q44597640 | ||
| Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences | Q44624787 | ||
| Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo | Q44727485 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance | Q44887107 | ||
| Dipeptidyl aminopeptidase IV in hospitalized patients and in galactosamine hepatitis of the rat: Activity and lectin affinity chromatography in serum and hepatic plasma membranes | Q44974021 | ||
| Proline in transmembrane domain of type II protein DPP-IV governs its translocation behavior through endoplasmic reticulum | Q45092446 | ||
| Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis | Q45254506 | ||
| Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis | Q45805661 | ||
| Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishme | Q45883055 | ||
| Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions | Q46071696 | ||
| DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue | Q46143099 | ||
| Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats | Q46309791 | ||
| The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding | Q46314551 | ||
| Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals | Q46443903 | ||
| Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. | Q46497442 | ||
| Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction | Q46733796 | ||
| Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form | Q46778176 | ||
| Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). | Q46818578 | ||
| Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis | Q84746720 | ||
| DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice β cells | Q84795883 | ||
| Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats | Q84959531 | ||
| Nonalcoholic fatty liver disease | Q85213566 | ||
| GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice | Q85538281 | ||
| Role of glucose-dependent insulinotropic polypeptide in adipose tissue inflammation of dipeptidylpeptidase 4-deficient rats | Q86115184 | ||
| Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions | Q87408607 | ||
| Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure? | Q88223737 | ||
| Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor | Q84187312 | ||
| Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review | Q84438092 | ||
| DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion | Q84543059 | ||
| Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure | Q33902623 | ||
| The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. | Q33932817 | ||
| Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies | Q33999894 | ||
| The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study | Q34024341 | ||
| Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system | Q34062829 | ||
| Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. | Q34226558 | ||
| DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus | Q34237983 | ||
| Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism | Q34365510 | ||
| Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database | Q34422144 | ||
| Trelagliptin: First Global Approval | Q34482528 | ||
| A Novel Consensus Motif in Fibronectin Mediates Dipeptidyl Peptidase IV Adhesion and Metastasis | Q34533162 | ||
| GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? | Q34547492 | ||
| Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. | Q34560590 | ||
| The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes | Q34583386 | ||
| Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice | Q34597496 | ||
| Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. | Q34651364 | ||
| A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide | Q34661843 | ||
| Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. | Q34668282 | ||
| Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 | ||
| Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice | Q34718822 | ||
| The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity | Q34733928 | ||
| Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome | Q35063234 | ||
| Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity | Q35067242 | ||
| Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial | Q35091620 | ||
| Seprase-dPPIV association and prolyl peptidase and gelatinase activities of the protease complex | Q35098605 | ||
| Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance | Q35144434 | ||
| RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice | Q35175990 | ||
| Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. | Q35189265 | ||
| Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials | Q35217932 | ||
| Characterization of dedifferentiating human mature adipocytes from the visceral and subcutaneous fat compartments: fibroblast-activation protein alpha and dipeptidyl peptidase 4 as major components of matrix remodeling | Q35224828 | ||
| Enhancing Incretin Action for the Treatment of Type 2 Diabetes | Q35545683 | ||
| Role of substance P in the regulation of glucose metabolism via insulin signaling-associated pathways | Q35590819 | ||
| The role of metformin in the management of NAFLD | Q35614956 | ||
| Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. | Q35809679 | ||
| CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status | Q36047622 | ||
| Endothelial actions of atrial and B-type natriuretic peptides | Q36159149 | ||
| Sitagliptin exerts an antinflammatory action | Q36201556 | ||
| A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase | Q36361511 | ||
| A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation | Q36477217 | ||
| Structure and function in dipeptidyl peptidase IV and related proteins | Q36478604 | ||
| Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes | Q36779756 | ||
| Dipeptidyl peptidase-4: a key player in chronic liver disease | Q36783164 | ||
| Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome | Q36799402 | ||
| Stromal cell derived factor-1alpha protects stem cell derived insulin-producing cells from glucotoxicity under high glucose conditions in-vitro and ameliorates drug induced diabetes in rats | Q36863430 | ||
| Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis | Q36933062 | ||
| A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? | Q36942123 | ||
| Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex. | Q37176935 | ||
| Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. | Q37195882 | ||
| Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro | Q37331331 | ||
| On the origin of serum CD26 and its altered concentration in cancer patients. | Q37532070 | ||
| CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. | Q37557487 | ||
| Therapeutic vaccine against DPP4 improves glucose metabolism in mice | Q37687552 | ||
| Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection | Q37739949 | ||
| Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. | Q37888004 | ||
| Incretin-based therapies | Q37894864 | ||
| Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. | Q37910902 | ||
| A review of gliptins in 2011. | Q37965612 | ||
| A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks | Q38104338 | ||
| Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. | Q38170080 | ||
| Peptide YY: more than just an appetite regulator | Q38219346 | ||
| Significance of CXCL12 in type 2 diabetes mellitus and its associated complications | Q38236202 | ||
| Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors | Q38248682 | ||
| The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. | Q38253620 | ||
| Incretin-based therapies | Q38279785 | ||
| MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice | Q38302500 | ||
| Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential. | Q38316922 | ||
| Teneligliptin : expectations for its pleiotropic action | Q38322300 | ||
| Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: Possible implications for the hypothalamic neuropeptidergic system | Q38340409 | ||
| Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets | Q46832007 | ||
| Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes | Q46878138 | ||
| Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia | Q46959131 | ||
| DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY. | Q47752660 | ||
| Increased circulating RANTES in type 2 diabetes | Q47834737 | ||
| Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. | Q47914982 | ||
| Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation | Q48386405 | ||
| Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes | Q49143530 | ||
| Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. | Q51254742 | ||
| Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study. | Q51308310 | ||
| A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. | Q51362571 | ||
| Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. | Q51378610 | ||
| Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus. | Q51394418 | ||
| Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 | ||
| Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis. | Q51535856 | ||
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. | Q51550359 | ||
| Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. | Q51697808 | ||
| Dipeptidyl peptidase IV (DDP IV) in NASH patients. | Q51727865 | ||
| Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. | Q52951285 | ||
| Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. | Q53207032 | ||
| Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. | Q54203121 | ||
| Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model. | Q54408588 | ||
| The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. | Q54485185 | ||
| DPP4 Gene DNA Methylation in the Omentum is Associated With Its Gene Expression and Plasma Lipid Profile in Severe Obesity | Q57316296 | ||
| Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells | Q57662605 | ||
| Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI | Q58039484 | ||
| Soluble CD26 / Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation In Vitro Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding | Q60617843 | ||
| Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activity | Q60617869 | ||
| MECHANISMS OF CD26/DIPEPTIDYL PEPTIDASE IV CYTOKINE-DEPENDENT REGULATION ON HUMAN ACTIVATED LYMPHOCYTES | Q62399778 | ||
| Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. | Q64998688 | ||
| Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver | Q67516828 | ||
| Changes of dipeptidylpeptidase IV as a membrane marker of lymphocytes in acute and chronic liver diseases--biochemical and cytochemical investigations | Q68321083 | ||
| Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice | Q71071202 | ||
| Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes | Q71926800 | ||
| Antibody-induced modulation of CD26 surface expression | Q72333319 | ||
| Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences | Q72660582 | ||
| Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes | Q73980584 | ||
| Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue | Q77531118 | ||
| Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure | Q79437872 | ||
| Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction | Q81011391 | ||
| Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing | Q81157658 | ||
| Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt | Q81317103 | ||
| Hepatic fibrogenesis | Q81544375 | ||
| The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats | Q82427245 | ||
| Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism | Q83011265 | ||
| Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury | Q83151449 | ||
| Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus | Q83618199 | ||
| Serum levels of calcitonin gene-related peptide and substance P are decreased in patients with diabetes mellitus and coronary artery disease | Q83689985 | ||
| Association of stromal cell-derived factor 1 genotype with diabetic foot syndrome and macrovascular disease in patients with type 2 diabetes | Q83840257 | ||
| Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors | Q83973657 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 386 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | DPP4 in Diabetes | |
| P478 | volume | 6 |
| Q90994473 | A new stability indicating reverse phase high performance liquid chromatography method for the determination of enantiomeric purity of a DPP-4 inhibitor drug linagliptin |
| Q33797281 | A novel iterative mixed model to remap three complex orthopedic traits in dogs |
| Q91638962 | A siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice |
| Q47250328 | Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease |
| Q33759119 | Adipose tissue supports normalization of macrophage and liver lipid handling in obesity reversal |
| Q46451003 | Ameliorative potential of linagliptin and/or calcipotriol on bleomycin-induced lung fibrosis: In vivo and in vitro study |
| Q46285672 | An extract from the Atlantic brown algae Saccorhiza polyschides counteracts diet-induced obesity in mice via a gut related multi-factorial mechanisms. |
| Q36939370 | Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules |
| Q26785454 | Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes |
| Q40354822 | Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study |
| Q35998458 | Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects |
| Q42036645 | Blood-Brain Barriers in Obesity. |
| Q36964223 | Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure |
| Q90244034 | Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice |
| Q52647767 | Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier. |
| Q51726149 | Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. |
| Q91969148 | Crosstalk between the Akt/mTORC1 and NF-κB signaling pathways promotes hypoxia-induced pulmonary hypertension by increasing DPP4 expression in PASMCs |
| Q38751579 | Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system |
| Q64972107 | DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy. |
| Q48229830 | DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics. |
| Q48178356 | DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review |
| Q51074054 | DPP4 regulates the inflammatory response in a rat model of febrile seizures. |
| Q91620510 | DPP8 is a novel therapeutic target for multiple myeloma |
| Q52806831 | Delayed allogeneic skin graft rejection in CD26-deficient mice. |
| Q55686880 | Development of a fluorogenic small substrate for dipeptidyl peptidase-4. |
| Q39103371 | Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. |
| Q58760269 | Dipeptidyl Peptidase-4 Is a Pro-Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells |
| Q89911717 | Dipeptidyl Peptidase-4 Is a Target Protein of Epigallocatechin-3-Gallate |
| Q92860558 | Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects |
| Q64896816 | Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. |
| Q92875235 | Dipeptidyl peptidase-4 is increased in the abdominal aortic aneurysm vessel wall and is associated with aneurysm disease processes |
| Q64107880 | Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes |
| Q41108574 | Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms |
| Q93181724 | Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population |
| Q61810243 | Enhancement of the Stability and Anti-DPPIV Activity of Hempseed Hydrolysates Through Self-Assembling Peptide-Based Hydrogels |
| Q100533893 | Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation |
| Q51119200 | Genetic interaction of DGAT2 and FAAH in the development of human obesity. |
| Q51738629 | Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain. |
| Q47174356 | High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-c |
| Q42709946 | High molecular weight PEGylation of human pancreatic polypeptide at position 22 improves stability and reduces food intake in mice |
| Q92556865 | Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients |
| Q64108658 | Incretins and SGLT-2i Therapy of Type 2 Diabetes - Real Life Study of Their Therapeutic and Economic Effects |
| Q59866796 | Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study |
| Q50782080 | Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy. |
| Q47138798 | Inhibiting DPP4 in a mouse model of HHT1 results in a shift towards regenerative macrophages and reduces fibrosis after myocardial infarction |
| Q61807342 | Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes |
| Q64260044 | Mechanism and Potential of Egg Consumption and Egg Bioactive Components on Type-2 Diabetes |
| Q91780179 | New Therapeutic Strategies for Type 2 Diabetes CME |
| Q36209787 | Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration |
| Q41094907 | Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction |
| Q64226372 | Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4 |
| Q51733912 | Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus. |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q26778329 | Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation |
| Q38614486 | Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients |
| Q48249200 | Significance of circulatory DPP4 activity in metabolic diseases. |
| Q48094071 | Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY. |
| Q64111503 | Sitagliptin protects against hypoxia/reoxygenation (H/R)-induced cardiac microvascular endothelial cell injury |
| Q57294140 | Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus |
| Q58784788 | Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum |
| Q89039974 | Structure⁻Activity Relationship and Molecular Docking of Natural Product Library Reveal Chrysin as a Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: An Integrated In Silico and In Vitro Study |
| Q41070039 | Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats. |
| Q92316034 | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect |
| Q50172954 | The emerging role of bone marrow adipose tissue in bone health and dysfunction |
| Q90291678 | The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from in silico to in vivo |
Search more.